Ketoconazole and clobetasol propionate cream and preparation method thereof

A technology of ketaxol cream and ketokang, which is applied to the field of ketocontazol cream and its preparation, can solve the problems of unsatisfactory skin penetration effect, bacterial or fungal infection, low bioavailability and the like, and achieves the promotion of local blood circulation, Increase the effect, enhance the effect of the drug

Active Publication Date: 2015-04-22
GUANGDONG SHUNFENG PHARMA
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, fungal infections are often accompanied by inflammation and the presence of bacteria. Antifungal drugs such as ketoconazole alone are often ineffective, and hormone anti-inflammatory drugs alone can easily induce further bacterial or fungal infections.
[0005] In addition, antifungal drugs for superficial fungal infections usually use external dosage forms such as ointments, which have the advantages of mild adverse reactions and a wide range of clinical applications, but also have disadvantages such as unsatisfactory transdermal effect and low bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ketoconazole and clobetasol propionate cream and preparation method thereof
  • Ketoconazole and clobetasol propionate cream and preparation method thereof
  • Ketoconazole and clobetasol propionate cream and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment one: the preparation of ketocontasol emulsifiable cream of the present invention

[0023] Weigh each component according to the formula in Table 1:

[0024] Table 1

[0025]

[0026]

[0027] Get the components in the formula shown in Table 1 respectively, according to the following steps, prepare the ketocontasol emulsifiable cream of the present invention:

[0028] 1) Take ketoconazole and clobetasol propionate, add them to the co-solvent, heat to 80±5°C, and stir to dissolve them completely;

[0029] 2) Take the oily base, heat it to 85±5°C, stir to melt it completely, keep it warm for 30 minutes, then cool it to 80±2°C, then add it into the solution obtained in step 1), and stir evenly to obtain the oil phase mixture;

[0030] 3) Take the water-soluble base, add chlorhexidine acetate, emulsifier, antioxidant and purified water, heat to 90±5°C, stir to dissolve it completely, keep it warm for 15 minutes, then cool to 80±2°C to obtain a water phase ...

Embodiment 2

[0032] Embodiment 2: Determination of Transdermal Absorption Effect

[0033] 1. Preparation of Ketocontasol Cream Control Example

[0034] 1) Take 10g of ketoconazole and 0.25g of clobetasol propionate, add it to 40g of dimethyl sulfoxide, heat to 80±5°C, stir to dissolve completely;

[0035] 2) Take 50g of white petrolatum, 65g of liquid paraffin, 70g of mono (d) glyceryl stearate and 50g of cetostearyl alcohol, heat it to 85±5°C, stir it to completely melt, keep it warm for 30 minutes and then cool it down to 80±5°C 2°C, then added to the solution obtained in step 1), and stirred evenly to obtain an oil phase mixture;

[0036] 3) Take 50g of polyethylene glycol, add 5g of chlorhexidine acetate, 50g of fatty alcohol polyoxyethylene ether, 0.1g of dibutyl hydroxytoluene and 602.65g of purified water, heat to 90±5°C, stir to dissolve completely, Cool to 80±2°C after heat preservation for 15 minutes to obtain the aqueous phase mixture;

[0037] 4) Add the water phase mixture ...

Embodiment 3

[0043] Embodiment three: therapeutic effect measurement

[0044] 1. Case selection:

[0045] Take 114 outpatient cases of Dermatology and Venereology Department of the Third Affiliated Hospital of Sun Yat-sen Medical University.

[0046] Inclusion criteria: patients with skin diseases diagnosed with tinea corporis, tinea manuum and pedis, tinea versicolor, eczema, dermatitis, regardless of gender or age.

[0047] The following cases are not included in the observation objects: (1) pregnant and lactating women; (2) those who have received radiotherapy two weeks before treatment, systemic immunosuppressants or anti-bacterial, anti-viral and anti-helminth drugs; ( 3) Those who have used external antifungal drugs two weeks before treatment or those who have taken antifungal drugs internally one month before treatment; (4) Those who have a history of allergy to imidazoles; (5) Those who have liver, kidney or blood diseases.

[0048] 2. Treatment method

[0049] Wash the affected...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses ketoconazole and clobetasol propionate cream which comprises the following components in percentage by weight: 1-6 percent of ketoconazole, 0.1-2 percent of chlorhexidine acetate, 0.01-0.15 percent of clobetasol propionate, 0.1-5 percent of methyl salicylate, 20-28 percent of a greasing base, 5-8 percent of a water-soluble base, 3-8 percent of an emulsifier, 3-6 percent of a cosolvent, 0.01-0.4 percent of an antioxidant, 0.1-1 percent of an essence and purified water in balancing amount. The ketoconazole and clobetasol propionate cream provided by the invention has the effects of fungus resistance, bacterium resistance and inflammation resistance and achieves a good transdermal effect.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a ketocontasol cream and a preparation method thereof. Background technique [0002] Fungal infection is divided into superficial, subcutaneous and systemic according to the level of infection. Superficial fungal infection is the most common clinical skin disease. Superficial fungal infections involve infection of the epidermis, hair, and nails and are usually caused by Microsporum, Trichophyton, Candida, and Malassezia. [0003] Ketoconazole is a synthetic imidazolidine derivative with broad-spectrum antifungal effects, especially bacteriostatic and bactericidal effects on dermatophytes, candida and Malassezia. Its mechanism of action is to inhibit the biosynthesis of fungal cell membrane ergosterol, affecting the permeability of the cell membrane and inhibiting its growth. [0004] However, fungal infections are often accompanied by inflammation and the pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/618A61P31/10A61P31/04A61P29/00A61P31/02A61K31/573A61K31/496A61K31/155
CPCA61K47/44A61K9/0014A61K9/06A61K31/155A61K31/496A61K31/573A61K31/618A61K2300/00
Inventor 麦文培柴将红梁勇坤梁吉东余良钟王北明
Owner GUANGDONG SHUNFENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap